Skip to main content

Advertisement

SpringerLink
Log in

The advanced glycation end product pentosidine correlates to IL-6 and other relevant inflammatory markers in rheumatoid arthritis

  • Original Article
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

Objective

Oxidative stress and inflammatory processes accelerate the formation of advanced glycation end products (AGE), e.g. of pentosidine. The aim of this study was to investigate the relationships between levels of pentosidine in serum and synovial fluid, proinflammatory cytokines, other markers of inflammatory activity, and the state of radiologically visible bone destruction in patients with rheumatoid arthritis (RA).

Objectives

One hundred thirty-three nondiabetic RA patients and 56 age-matched, healthy subjects were included. Serum and synovial fluid pentosidine, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and rheumatoid factor levels were determined. In 30 patients, the proinflammatory cytokines interleukin (IL)-1β, IL-6, and TNF-α and the soluble receptors sIL-2R, sIL-6R, sTNF-α, and RI/RII were also measured.

Results

Serum levels of pentosidine were on average significantly higher in RA patients than in healthy subjects and correlated significantly to ESR, CRP, and serum levels of IL-6. Serum and synovial fluid pentosidine did not show any differences. Rheumatoid factor-positive RA patients had higher pentosidine levels in the synovial fluid than rheumatoid factor-negative patients. Correlations could not be found between pentosidine and the other cytokines or cytokine receptors measured.

Conclusion

The binding of AGE on cell receptors induces activation of nuclear factor kappa B, resulting in enhanced synthesis of proinflammatory cytokines. Moreover, AGE generation may also lead to the formation of new, immunologically relevant epitopes at synovial proteins. Both mechanisms could contribute to initiation and perpetuation of the inflammatory and destructive processes in RA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Zvaifler NJ, Firestein GS (1994) Pannus and pannocytes. Alternative models of joint destruction in rheumatoid arthritis. Arthritis Rheum 37:783–789

    CAS  PubMed  Google Scholar 

  2. Kinne RW, Palombo-Kinne E, Emmrich F (1995) Activation of synovial fibroblasts in rheumatoid arthritis. Ann Rheum Dis 54:501–504

    CAS  Google Scholar 

  3. Panayi GS, Lanchbury JS, Kingsley GH (1992) The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. Arthritis Rheum 35:729–734

    CAS  PubMed  Google Scholar 

  4. Fox DA (1997) The role of T cells in the immunopathogenesis of rheumatoid arthritis. Arthritis Rheum 40:598–609

    CAS  PubMed  Google Scholar 

  5. Edmonds SE, Ellis G, Gaffney K, Archer J, Blake DR (1995) Hypoxia and the rheumatoid joint: immunological and therapeutic implications. Scand J Rheumatol 24 [Suppl 101]:163–168

  6. Vlassara H, Palace MR (2002) Diabetes and advanced glycation end products. J Intern Med 251:87–101

    Article  CAS  PubMed  Google Scholar 

  7. Vlassara H (2001) The AGE-receptor in the pathogenesis of diabetic complications. Diabetes Metab Res Rev 17:436–443

    Article  CAS  PubMed  Google Scholar 

  8. Hofmann MA, Schiekofer S, Isermann B, Treusch A, Kanitz M, Klevesath MS, Joswing M, Morcos M, Weiss T, Borcea V, Khalet AM, Amiral J, Tritschler H, Wahl P, Ziegler R, Ritz E, Bierhaus A, Nawroth P (1999) Peripheral blood mononuclear cells isolated from patients with diabetic nephropathy demonstrated increased activation of the oxidative-stress sensitive transcription NF-κB. Diabetologia 42:222–232

    Article  CAS  PubMed  Google Scholar 

  9. Daoud S, Schinzel R, Neumann A, Loske C, Fraccarollo D, Diez C, Simm A (2001) Advanced glycation end products: activator of cardiac remodeling in primary fibroblasts from adult rat heart. Mol Med 7:543–551

    CAS  PubMed  Google Scholar 

  10. Takahashi M, Suzuki M, Kushida K, Miyamoto S, Inoue T (1997) Relationship between pentosidine levels in serum and urine and activity in rheumatoid arthritis. Br J Rheumatol 36:637–642

    Article  CAS  PubMed  Google Scholar 

  11. Miyata T, Ishiguro N, Yasuda Y, Ito T, Nangaku M, Iwata H, Kurokawa K (1998) Increased pentosidine, an advanced glycation end product, in plasma and synovial fluid from patients with rheumatoid arthritis and its relation with inflammatory markers. Biochem Biophys Res Commun 244:45–49

    Article  CAS  PubMed  Google Scholar 

  12. Drinda S, Franke S, Canet CC, Petrow P, Bräuer R, Hüttich C, Stein G, Hein G (2002) Identification of Ne-carboxymethyllysine in the synovial tissue of patients with rheumatoid arthritis. Ann Rheum Dis 61:488–492

    Article  CAS  PubMed  Google Scholar 

  13. Drinda S Franke S, Rüster M, Petrow P, Pullig O, Stein G, Hein G (2004) Identification of the receptor of AGE (advanced glycation end products) in synovial tissue of patients with rheumatoid arthritis. Rheumatol Int (accepted for publication)

  14. Hein G, Wiegand R, Lehmann G, Stein G, Franke S (2003) Advanced glycation end-products pentosidine and Ne-carboxymethyllysine are elevated in serum of patients with osteoporosis. Rheumatology 42:1242–1246

    Article  CAS  PubMed  Google Scholar 

  15. Miyata T, Notoya K, Yoshida K, Horie K, Maeda K, Kurokawa K, Taketomie S (1997) Advanced glycation end products enhance osteoclast-induced bone resorption in cultured mouse unfractionated bone cells and in rats implanted subcutaneously with devitalized bone particles. J Am Soc Nephrol 8:260–270

    CAS  PubMed  Google Scholar 

  16. Hein G, Franke S (2002) Are advanced glycation end-product-modified proteins of pathogenetic importance in fibromyalgia? Rheumatology 41:1163–1167

    Google Scholar 

  17. Miyata T, Ueda Y, Shinzato T et al (1996) Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: renal implications in the pathophysiology of pentosidine. J Am Soc Nephrol 7:1198–1206

    CAS  PubMed  Google Scholar 

  18. Schmidt AM, Hori O, Brett J, Yan SD, Wautier JL, Stern D (1994) Cellular receptors for advanced glycation end products. Implication for the induction of oxidative stress and cellular dysfunction in the pathogenesis of vascular lesions. Atheroscler Thromb 14:1521–1528

    CAS  Google Scholar 

  19. Nawroth PP, Bierhaus A, Vogel GE, Hofmann MA, Zumbach M, Wahl P, Ziegler R (1999) Nonenzymatic glycation and oxidative stress in chronic diseases and diabetes mellitus [German]. Med Klin 94:29–38

    CAS  Google Scholar 

  20. Makarov SS (2001) NF-kappa B in rheumatoid arthritis: a pivotal regulator of inflammation, hyperplasia and tissue destruction. Arthritis Res 3:200–206

    Article  CAS  PubMed  Google Scholar 

  21. Handel ML, McMorrow LB, Gravallese EM (1995) Nuclear factor-kappa B in rheumatoid synovium. Localization of p50 and p65. Arthritis Rheum 38:1762–1770

    CAS  PubMed  Google Scholar 

  22. Georganas C, Liu H, Perlman H, Hoffmann A, Thimmapaya B, Pope RM (2000) Regulation of IL-6 and IL-8 expression in rheumatoid arthritis synovial fibroblasts: the dominant role for NF-kappa B but not C/EBP beta or c-Jun. J Immunol 165:7199–7206

    Google Scholar 

  23. Yoshida S, Kato T, Sakurada S et al (1999) Inhibition of IL-6 and IL-8 from cultured rheumatoid synovial fibroblasts by treatment with aurothioglucose. Int Immunol 11:151–158

    Google Scholar 

  24. Sakurada S, Kato T, Okamoto T (1996) Induction of cytokines and ICAM-1 by proinflammatory cytokines in primary rheumatoid synovial fibroblasts and inhibition by N-acetyl-L-cysteine and aspirin. Int Immunol 8:1483–1493

    Google Scholar 

  25. Tomita T, Takano H, Tomota N et al (2000) Transcription factor decoy for NFkB inhibits cytokine and adhesion molecule expression in synovial cells derived from rheumatoid arthritis. Rheumatology 39:749–757

    Article  CAS  PubMed  Google Scholar 

  26. Hofbauer LC, Heufelder AE (2001) The role of osteoprotegerin and receptor activator of nuclear factor kB ligand in the pathogenesis and treatment of rheumatoid arthritis. Arthritis Rheum 44:253–259

    Article  CAS  PubMed  Google Scholar 

  27. Li P, Sanz I, O’Keefe RJ, Schwarz EM (2000) NF-kappa B regulates VCAM-1 expression on fibroblast-like synoviocytes. J Immunol 164:5990–5997

    Google Scholar 

  28. Bond M, Baker AH, Newby AC (1999) Nuclear factor kappa B activity is essential for matrix metalloproteinase-1 and -3 upregulation in rabbit dermal fibroblasts. Biochem Biophys Res Commun 264:561–567

    Article  CAS  PubMed  Google Scholar 

  29. Hofbauer LC, Heufelder AE (2001) Role of receptor activator of nuclear factor κB ligand and osteoprotegerin in bone cell biology. J Mol Med 79:243–253

    Article  CAS  PubMed  Google Scholar 

  30. Takagi M, Kasayama S, Yamamoto T et al (1997) Advanced glycation endproducts stimulate interleukin-6 production by human bone derived cells. J Bone Miner Res 12:439–446

    CAS  PubMed  Google Scholar 

  31. Yang C, Acil Y, Muller PK (1994) An unique antigenic determinant on collagen II closely associated with age related abnormal modification. Biochem Biophys Res Commun 16:1641–1649

    Article  Google Scholar 

  32. Michaelsson E, Malmstrom V, Reis S, Engstrom A, Burkhardt H, Holmdahl R (1994) T cell recognition of carbohydrates on type II collagen. J Exp Med 180:745–749

    Article  CAS  PubMed  Google Scholar 

  33. Charriere G, Hartmann DJ, Vignon E, Ronziere MC, Herbage D, Ville G (1988) Antibodies to types I, II, IX and XI collagen in the serum of patients with rheumatic diseases. Arthritis Rheum 31:325–332

    CAS  PubMed  Google Scholar 

  34. Cook AD, Rowley MJ, Mackay IR, Gough A, Emery P (1996) Antibodies to type II collagen in early rheumatoid arthritis. Correlation with disease progression. Arthritis Rheum 39:1720–1727

    CAS  PubMed  Google Scholar 

  35. Terato K, Shimozuru Y, Katayama K, Takemitsu Y, Yamashita I, Miyatsu M, Fujii K, Sagara M, Kobayashi S, Goto M et al (1990) Specificity of antibodies to type II collagen in rheumatoid arthritis. Arthritis Rheum 33:1493–1500

    CAS  PubMed  Google Scholar 

  36. Wooley PH, Luthra HS, Singh SK, Huse AR, Stuart JM, David CS (1984) Passive transfer of arthritis to mice by injection of human anti-type II collagen antibody. Mayo Clin Proc 59:737–743

    CAS  PubMed  Google Scholar 

  37. Tai AW, Newkirk MM (2000) An autoantibody targeting glycated IgG is associated with elevated serum immune complexes in rheumatoid arthritis (RA). Clin Exp Immunol 120:188–193

    Article  CAS  PubMed  Google Scholar 

  38. Ligier S, Fortin PR, Newkirk MM (1998) A new antibody in rheumatoid arthritis targeting glycated IgG: IgM anti-IgG-AGE. Br J Rheumatol 37:1307–1314

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Rheumatology and Osteology, Department of Internal Medicine III, Friedrich Schiller University of Jena, 07740, Jena, Germany

    Gert E. Hein, Markus Köhler, Peter Oelzner, Günter Stein & Sybille Franke

Authors
  1. Gert E. Hein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Markus Köhler
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Oelzner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Günter Stein
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sybille Franke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gert E. Hein.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hein, G.E., Köhler, M., Oelzner, P. et al. The advanced glycation end product pentosidine correlates to IL-6 and other relevant inflammatory markers in rheumatoid arthritis. Rheumatol Int 26, 137–141 (2005). https://doi.org/10.1007/s00296-004-0518-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-004-0518-1

Keywords

Search

Navigation